Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumors

Detalhes bibliográficos
Autor(a) principal: Nunes, Sofia C.
Data de Publicação: 2023
Outros Autores: Sousa, Joana, Silva, Fernanda, Silveira, Margarida, Guimarães, António, Serpa, Jacinta, Félix, Ana, Gonçalves, Luís G.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10362/159814
Resumo: Funding Information: The institutions are funded by Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES, Portugal) through national funds to iNOVA4Health (UIDB/04462/2020 and UIDP/04462/2020), to MOSTMICRO-ITQB (UIDB/04612/2020 and UIDP/04612/2020) and the Associated Laboratory LS4FUTURE (LA/P/0087/2020). The NMR data was acquired at CERMAX, ITQB-NOVA, Oeiras, Portugal with equipment funded by FCT, project AAC 01/SAICT/2016 and at CICS-UBI (Health Sciences Research Centre—University of Beira Interior) with equipment acquired in the scope of the project POVT-0439-FEDER-00001. Luis G. Gonçalves was financed by a FCT contract according to DL57/2016, [SFRH/BPD/111100/2015]. Publisher Copyright: © 2023 by the authors.
id RCAP_6972fa87cb92a29971824abc9f3e286c
oai_identifier_str oai:run.unl.pt:10362/159814
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumorsbenign ovarian tumorsbiomarkersborderline ovarian tumorscancer progressionmalignant ovarian tumorsNMR metabolomicsovarian cancerserumEndocrinology, Diabetes and MetabolismBiochemistryMolecular BiologySDG 3 - Good Health and Well-beingFunding Information: The institutions are funded by Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES, Portugal) through national funds to iNOVA4Health (UIDB/04462/2020 and UIDP/04462/2020), to MOSTMICRO-ITQB (UIDB/04612/2020 and UIDP/04612/2020) and the Associated Laboratory LS4FUTURE (LA/P/0087/2020). The NMR data was acquired at CERMAX, ITQB-NOVA, Oeiras, Portugal with equipment funded by FCT, project AAC 01/SAICT/2016 and at CICS-UBI (Health Sciences Research Centre—University of Beira Interior) with equipment acquired in the scope of the project POVT-0439-FEDER-00001. Luis G. Gonçalves was financed by a FCT contract according to DL57/2016, [SFRH/BPD/111100/2015]. Publisher Copyright: © 2023 by the authors.Ovarian cancer is the major cause of death from gynecological cancer and the third most common gynecological malignancy worldwide. Despite a slight improvement in the overall survival of ovarian carcinoma patients in recent decades, the cure rate has not improved. This is mainly due to late diagnosis and resistance to therapy. It is therefore urgent to develop effective methods for early detection and prognosis. We hypothesized that, besides being able to distinguish serum samples of patients with ovarian cancer from those of patients with benign ovarian tumors, 1H-NMR metabolomics analysis might be able to predict the malignant potential of tumors. For this, serum 1H-NMR metabolomics analyses were performed, including patients with malignant, benign and borderline ovarian tumors. The serum metabolic profiles were analyzed by multivariate statistical analysis, including principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) methods. A metabolic profile associated with ovarian malignant tumors was defined, in which lactate, 3-hydroxybutyrate and acetone were increased and acetate, histidine, valine and methanol were decreased. Our data support the use of 1H-NMR metabolomics analysis as a screening method for ovarian cancer detection and might be useful for predicting the malignant potential of borderline tumors.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)iNOVA4Health - pólo NMSInstituto de Tecnologia Química e Biológica António Xavier (ITQB)RUNNunes, Sofia C.Sousa, JoanaSilva, FernandaSilveira, MargaridaGuimarães, AntónioSerpa, JacintaFélix, AnaGonçalves, Luís G.2023-11-10T22:08:55Z2023-092023-09-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10362/159814eng2218-1989PURE: 73149524https://doi.org/10.3390/metabo13090989info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T05:42:18Zoai:run.unl.pt:10362/159814Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:57:43.537211Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumors
title Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumors
spellingShingle Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumors
Nunes, Sofia C.
benign ovarian tumors
biomarkers
borderline ovarian tumors
cancer progression
malignant ovarian tumors
NMR metabolomics
ovarian cancer
serum
Endocrinology, Diabetes and Metabolism
Biochemistry
Molecular Biology
SDG 3 - Good Health and Well-being
title_short Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumors
title_full Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumors
title_fullStr Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumors
title_full_unstemmed Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumors
title_sort Peripheral Blood Serum NMR Metabolomics Is a Powerful Tool to Discriminate Benign and Malignant Ovarian Tumors
author Nunes, Sofia C.
author_facet Nunes, Sofia C.
Sousa, Joana
Silva, Fernanda
Silveira, Margarida
Guimarães, António
Serpa, Jacinta
Félix, Ana
Gonçalves, Luís G.
author_role author
author2 Sousa, Joana
Silva, Fernanda
Silveira, Margarida
Guimarães, António
Serpa, Jacinta
Félix, Ana
Gonçalves, Luís G.
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)
iNOVA4Health - pólo NMS
Instituto de Tecnologia Química e Biológica António Xavier (ITQB)
RUN
dc.contributor.author.fl_str_mv Nunes, Sofia C.
Sousa, Joana
Silva, Fernanda
Silveira, Margarida
Guimarães, António
Serpa, Jacinta
Félix, Ana
Gonçalves, Luís G.
dc.subject.por.fl_str_mv benign ovarian tumors
biomarkers
borderline ovarian tumors
cancer progression
malignant ovarian tumors
NMR metabolomics
ovarian cancer
serum
Endocrinology, Diabetes and Metabolism
Biochemistry
Molecular Biology
SDG 3 - Good Health and Well-being
topic benign ovarian tumors
biomarkers
borderline ovarian tumors
cancer progression
malignant ovarian tumors
NMR metabolomics
ovarian cancer
serum
Endocrinology, Diabetes and Metabolism
Biochemistry
Molecular Biology
SDG 3 - Good Health and Well-being
description Funding Information: The institutions are funded by Fundação para a Ciência e a Tecnologia/Ministério da Ciência, Tecnologia e Ensino Superior (FCT/MCTES, Portugal) through national funds to iNOVA4Health (UIDB/04462/2020 and UIDP/04462/2020), to MOSTMICRO-ITQB (UIDB/04612/2020 and UIDP/04612/2020) and the Associated Laboratory LS4FUTURE (LA/P/0087/2020). The NMR data was acquired at CERMAX, ITQB-NOVA, Oeiras, Portugal with equipment funded by FCT, project AAC 01/SAICT/2016 and at CICS-UBI (Health Sciences Research Centre—University of Beira Interior) with equipment acquired in the scope of the project POVT-0439-FEDER-00001. Luis G. Gonçalves was financed by a FCT contract according to DL57/2016, [SFRH/BPD/111100/2015]. Publisher Copyright: © 2023 by the authors.
publishDate 2023
dc.date.none.fl_str_mv 2023-11-10T22:08:55Z
2023-09
2023-09-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10362/159814
url http://hdl.handle.net/10362/159814
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 2218-1989
PURE: 73149524
https://doi.org/10.3390/metabo13090989
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138159511994368

Registros relacionados